Explore a question
Changes in desire, comfort during sex, and closeness with a partner are common in midlife, and often hard to bring up — even with a clinician. Some of these changes have physical causes with well-studied options; others are bound up with relationships, stress, body image, and everything else going on at this stage of life. Both are worth taking seriously.
Decreased libido or sex drive
Decreased libido is commonly reported and has a plausible hormonal pathway through GSM-related pain, but a direct hormone-to-desire link independent of pain or other causes is weaker and less consistently supported.
Early, limited, mixed, or indirect research. Some people may find this useful, but we can't be confident about the average effect.
What does this grade mean?Pain with intercourse / vulvar irritation
Pain with intercourse and vulvar irritation are well-established, directly menopause-linked symptoms (dyspareunia, part of GSM), strongly supported by a 2024 systematic review of 46 RCTs.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Vaginal dryness
Vaginal dryness is a well-established, directly menopause-linked symptom, part of genitourinary syndrome of menopause (GSM) and supported by extensive RCT evidence for its treatments.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
From qualitative research — what women report about their experiences, not treatment effects or how common something is.
An 18-study synthesis across 11 countries found some women reported decreased sexual desire while others reported stable or increased desire - variation the review linked to relationship quality, body image, sexual history, and culture, not menopause alone.
There is reasonably consistent research, but important limitations or unanswered questions remain.
Partner support was described as variable in qualitative accounts - some women described understanding partners, others dismissiveness or discomfort discussing menopause. Talking about sexual concerns, with partners or professionals, was itself identified as a major and often difficult theme.
Early, limited, mixed, or indirect research. Some people may find this useful, but we can't be confident about the average effect.
What does this grade mean?Reviews caution that concurrent midlife events - caregiving, children leaving home, bereavement, career pressures - make it difficult to attribute relational or workplace change to menopause alone.
Early, limited, mixed, or indirect research. Some people may find this useful, but we can't be confident about the average effect.
What does this grade mean?Desire and intimacy are shaped by many things at once, so research can rarely say how much any one change is due to menopause. The lived-experience findings below come from qualitative studies — they describe what women report, not how common something is or what will help a particular person.
Grouped by type, not ranked. An evidence grade describes the research — it doesn't tell you whether an option is suitable, safe, or right for you.
Low-dose vaginal estrogen
Low-dose vaginal estrogen is a well-established, effective treatment for genitourinary syndrome of menopause, with a strong safety profile due to minimal systemic absorption.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
Both sides are independently sourced and graded — read the grades, not just the labels.
Evidence-based benefit for a specific, well-defined use
Physiological-dose testosterone therapy has strong, multi-society-endorsed evidence for treating hypoactive sexual desire disorder specifically — improving satisfying sexual events and reducing sexual distress in postmenopausal women. Evidence does not support using it for energy, mood, or general well-being, and prescribing outside the HSDD indication isn't well supported.
Multiple high-quality studies generally point in the same direction, though no study can guarantee an individual outcome.
No FDA-approved product, and real long-term safety gaps
No testosterone product is FDA-approved for women in the U.S., forcing off-label or compounded use with inconsistent dosing. Long-term cardiovascular and breast-cancer safety data genuinely don't exist for this use, and pellet formulations specifically carry documented dosing and safety concerns that clinical bodies have warned against.
There is reasonably consistent research, but important limitations or unanswered questions remain.
Questions you save go to Your Record and can be added to your next Doctor Prep.
Sex has become uncomfortable or painful. What options could help?
My interest in sex has changed and it's bothering me. Is that something we can talk about?
Could any of my medicines be affecting my desire or comfort?
Is testosterone something that could be considered for me, and what are the unknowns?
Want to keep track over time? Record what you've noticed in Today